胃癌 中国就医指南

Gastric cancer, also known as stomach cancer, is a malignant neoplasm arising from the epithelial lining of the gastric mucosa—most commonly adenocarcinoma (accounting for over 90% of cases). It typically develops through a multistep carcinogenic cascade: chronic gastritis → atrophic gastritis → intestinal metaplasia → dysplasia → invasive adenocarcinoma. This progression is strongly associated with persistent Helicobacter pylori infection, which induces chronic inflammation, oxidative DNA damage, and aberrant cell proliferation. Other pathogenic mechanisms include Epstein-Barr virus (EBV) integration in ~10% of cases, microsatellite instability (MSI-H), and CDH1 germline mutations in hereditary diffuse gastric cancer (HDGC). Globally, gastric cancer ranks fifth in incidence and fourth in cancer-related mortality, with an estimated 969,000 new cases and 738,000 deaths annually (GLOBOCAN 2022). Incidence is markedly higher in East Asia (especially Korea, Japan, and China), Eastern Europe, and parts of Central and South America—regions where high-salt diets, smoked/preserved foods, smoking, and widespread H. pylori prevalence converge. In China alone, gastric cancer accounts for approximately 40% of global cases, with age-standardized incidence rates exceeding 25 per 100,000 in high-risk provinces. Key modifiable risk factors include long-standing H. pylori infection (relative risk ~3–6), tobacco use (2-fold increased risk), excessive salt intake, low fruit/vegetable consumption, and heavy alcohol consumption. Non-modifiable risks include male sex (2:1 male-to-female ratio), advanced age (median diagnosis at 68 years), family history, blood type A, and genetic syndromes such as Lynch syndrome or HDGC. Early-stage disease is often asymptomatic; later symptoms—including persistent epigastric pain, early satiety, unintentional weight loss, nausea, vomiting (sometimes with hematemesis), and iron-deficiency anemia—frequently indicate locally advanced or metastatic disease. Diagnosis relies on upper gastrointestinal endoscopy with systematic biopsy, enhanced by chromoendoscopy or magnification techniques in high-prevalence regions. Staging integrates EUS, contrast-enhanced CT, and sometimes PET-CT or diagnostic laparoscopy. Quality of life is profoundly impacted: patients experience significant nutritional compromise due to impaired gastric digestion and motility, fatigue from chronic inflammation and anemia, anxiety related to prognosis (5-year survival drops from >70% in Stage I to <10% in Stage IV), and psychosocial burden affecting work capacity, social engagement, and caregiver dynamics. Palliative care integration—addressing pain, nausea, depression, and nutritional support—is essential across all stages to preserve dignity and functional independence.

# 胃癌治疗方案与费用明细（消化内科）

一、非手术治疗方案

适用人群：早期高龄/合并严重基础病无法耐受手术者、T1a期黏膜内癌（EMR/ESD禁忌者）、晚期姑息治疗患者。

• •内镜下治疗（EMR/ESD）：适用于分化好、无溃疡、≤2 cm黏膜内癌。检查费（胃镜+活检+病理+超声内镜）：2,800–4,200元；治疗费（含麻醉、耗材）：12,000–25,000元。
• •系统药物治疗：一线化疗（奥沙利铂+替吉奥）6周期，药费+输注+监测：38,000–65,000元；靶向（曲妥珠单抗）联合化疗：12–18万元/年；免疫治疗（纳武利尤单抗）：96,000–156,000元/年（按体重及疗程计）。

二、手术治疗方案

适用人群：T1b–T4aN0–3M0可切除胃癌，心肺功能可耐受全麻。

• •腹腔镜根治术（D2淋巴结清扫）：术前检查（增强CT+胃镜+心肺评估）：4,500–6,200元；手术+麻醉+住院（12–15天）：58,000–92,000元。
• •开腹根治术：费用略低，约52,000–85,000元（含术后营养支持及并发症管理）。

三、特殊复杂情况

• •局部晚期（cT4b/N+）新辅助治疗：化疗±放疗后手术，全程费用12–20万元；
• •腹膜转移（P0–P1）：HIPEC（腹腔热灌注化疗）+系统治疗，单次HIPEC 28,000元，全程≥15万元；
• •肝/肺寡转移：多学科联合消融/切除+全身治疗，总费用22–35万元。

四、方案快速选择指南

• •预算≤8万元+早期无转移：首选ESD或腹腔镜手术；
• •预算10–20万元+局部进展期：新辅助化疗+腹腔镜根治术；
• •晚期/转移/高龄体弱：一线靶向/免疫联合化疗，优先纳入临床试验（部分免费）。